BIM
VRTX icon

Baldwin Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Baldwin Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.38M Buy
16,870
+1,208
+8% +$535K 0.81% 17
2026
Q1 		$6.99M Buy
15,662
+108
+0.7% +$50.4K 0.82% 16
2025
Q4 		$7.05M Sell
15,554
-194
-1% -$83.6K 0.8% 15
2025
Q3 		$6.17M Buy
15,748
+1,207
+8% +$504K 0.71% 17
2025
Q2 		$6.47M Buy
14,541
+711
+5% +$328K 0.78% 13
2025
Q1 		$6.71M Buy
13,830
+1,271
+10% +$592K 0.81% 13
2024
Q4 		$5.06M Buy
12,559
+668
+6% +$310K 0.66% 16
2024
Q3 		$5.53M Buy
11,891
+135
+1% +$64.8K 0.69% 18
2024
Q2 		$5.51M Buy
11,756
+1,407
+14% +$611K 0.75% 16
2024
Q1 		$4.33M Buy
10,349
+976
+10% +$413K 0.59% 20
2023
Q4 		$3.81M Buy
9,373
+347
+4% +$128K 0.6% 25
2023
Q3 		$3.14M Buy
9,026
+533
+6% +$186K 0.52% 28
2023
Q2 		$2.99M Buy
8,493
+130
+2% +$43.8K 0.49% 32
2023
Q1 		$2.63M Buy
8,363
+52
+0.6% +$15.6K 0.47% 37
2022
Q4 		$2.4M Buy
8,311
+535
+7% +$163K 0.43% 41
2022
Q3 		$2.25M Buy
7,776
+259
+3% +$74.5K 0.46% 36
2022
Q2 		$2.12M Sell
7,517
-99
-1% -$26.5K 0.4% 43
2022
Q1 		$1.99M Buy
7,616
+917
+14% +$218K 0.3% 57
2021
Q4 		$1.47M Buy
6,699
+649
+11% +$126K 0.23% 80
2021
Q3 		$1.1M Sell
6,050
-55
-0.9% -$10.7K 0.19% 92
2021
Q2 		$1.23M Buy
6,105
+240
+4% +$50.2K 0.21% 85
2021
Q1 		$1.26M Buy
+5,865
New +$1.29M 0.23% 81

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Baldwin Investment Management's VRTX Position: Q2 2026 in Review

Baldwin Investment Management increased its Vertex Pharmaceuticals (VRTX) stake by 7.7% in Q2 2026, buying an estimated $535K and bringing the position to 16,870 shares worth $8.38M. The position accounts for 0.81% of the portfolio, ranked #17.

Baldwin Investment Management first reported a position in VRTX in Q1 2021 and has held it in 22 quarters since. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Baldwin Investment Management held 16,870 shares of Vertex Pharmaceuticals worth $8.38M as of Q2 2026.
  • Baldwin Investment Management bought 1,208 Vertex Pharmaceuticals shares in Q2 2026, an estimated $535K.
  • Vertex Pharmaceuticals made up 0.81% of Baldwin Investment Management's portfolio in Q2 2026, its #17 holding.
  • Baldwin Investment Management first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Baldwin Investment Management's 13F filing for Q2 2026, filed 28 Jul 2026.